Safe-Cross vessel wall detection technology approved in the US:
This article was originally published in Clinica
Kensey Nash has received US FDA 510(k) clearance for its vessel wall detection technology. The Safe-Cross RF CTO system combines a guidance system and radiofrequency energy to safely cross and recanalise chronic total occlusions in the coronary and peripheral arteries. The clearance allows Kensey Nash, of Exton, Pennsylvania, to incorporate a new interferometer with greater dynamic range into the Safe-Cross console. This technology will allow the system to sense the vessel wall farther in advance, allowing the operator more time to adjust the direction of the wire. The updated console will undergo a period of user evaluations prior to broader market introduction. Kensey Nash expects to CE mark the new technology later this year.
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.